Email This

A 44-Year-Old Man With Chronic Phase Chronic Myelogenous Leukemia, a History of Asthma, and a Poor Response to Imatinib Mesylate CME

Francis J. Giles, MB, MD, FRCPI, FRCPath Author Information and Disclosures

Release Date: April 23, 2008; Valid for credit through April 23, 2009

Credits Available

Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™ for physicians

This program was created solely for use on eMedicine.

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

A 44-Year-Old Man With Chronic Phase Chronic Myelogenous Leukemia, a History of Asthma, and a Poor Response to Imatinib Mesylate Francis J. Giles, MB, MD, FRCPI, FRCPath

Go to CME Test Questions

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Learning Objectives

Upon completion of this activity, participants should be better able to:

Discuss the results of clinical trials evaluating pharmacologic treatments for CML;
Evaluate the role of molecular testing and mutation analysis and of differentiating suboptimal responses and resistance;
Evaluate how dose optimization and novel agents can be integrated into the treatment algorithms for patients with CML;
Recognize the importance of monitoring patients with CML.

Author Disclosures

Francis J. Giles, MB, MD, FRCPI, FRCPath
Disclosure: Investigator: Amgen, Bristol-Myers Squibb, Kosan Biosciences, Merck & Co., Inc., Novartis, Pfizer Inc, Structural GenomiX.

education | outcomes | science is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

education | outcomes | science designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. The American Medical Association has determined that non-US licensed physicians who participate in this CME activity are eligible for AMA PRA Category 1 Credit™.

Contact This Provider